Leg-saving cell therapy
Aastrom has developed a patient-specific cell therapy using a proprietary cell culture process. Its lead project in Critical Limb Ischaemia (CLI) aims to increase amputation-free survival in patients with blocked leg arteries. Strong Phase II data, to be fully reported 12-16 November, has led to a pivotal 594 patient Phase III starting Q411. A dilated heart indication has Phase II data with Phase IIb starting H112.